If you look at the data as a whole and especially the six studies we cite in our editorial the findings suggest that the cardiovascular and metabolic benefits of GLP-1 drugs extend beyond weight loss, indicating other mechanisms, such as anti-inflammatory or kidney and liver effects, may play a major role
Does injecting tirzepatide in the morning versus evening change how much weight I'll lose
Here are some of the most common causes of a false-positive pregnancy test
neXt breakthrough in healthcare may not be treating disease, but delaying aging itself
Wegovy (semaglutide) is a GLP-1 receptor agonist specifically licensed by the MHRA for weight management in adults with obesity, recommended by NICE within specialist NHS services
For clinicians working in endocrinology, metabolic medicine, or hormone optimization, this combination merits evaluation within a structured clinical framework: comprehensive pre-treatment assessment, individualized dosing based on patient physiology, regular IGF-1 monitoring, and integration with broader hormonal and metabolic management